Home/Pipeline/S-217622 (Ensitrelvir)

S-217622 (Ensitrelvir)

COVID-19

Phase 3Active (Approved in Japan)

Key Facts

Indication

COVID-19

Phase

Phase 3

Status

Active (Approved in Japan)

Company

Shionogi

About Shionogi

Shionogi is a premier, discovery-based Japanese pharmaceutical company with a 65+ year legacy in antibiotic innovation and a mission to supply the best possible medicine to protect patient health. The company has successfully diversified its pipeline beyond its core infectious disease expertise into antivirals, CNS disorders, and rare diseases, while maintaining a steadfast commitment to combating antimicrobial resistance (AMR). Its strategy combines deep in-house R&D capabilities with strategic global partnerships and licensing to accelerate development and commercialize novel therapeutics for serious unmet medical needs worldwide.

View full company profile

Therapeutic Areas

Infectious Diseases Central Nervous System (CNS)Rare Diseases Virology Oncology

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active